Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Philip J Mease; Philip S Helliwell; Kasper Fjellhaugen Hjuler; Kyle Raymond; Iain McInnes

doi:10.1136/annrheumdis-2019-216835

Article info

PDF

PDF +
Supplementary
Material

XML

Psoriatic arthritis

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Authors

Philip J Mease Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA PubMed articles Google scholar articles
Philip S Helliwell Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK PubMed articles Google scholar articles
Kasper Fjellhaugen Hjuler Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark PubMed articles Google scholar articles
Kyle Raymond Medical Department, Leo Pharma, Ballerup, Denmark PubMed articles Google scholar articles
Iain McInnes Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK PubMed articles Google scholar articles

Correspondence to Dr Philip J Mease, Rheumatology Research, Swedish Medical Center, Seattle, WA 98122, USA; pmease{at}philipmease.com

View Full Text

Citation

Mease PJ, Helliwell PS, Hjuler KF, et al

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Annals of the Rheumatic Diseases 2021;80:185-193.

Publication history

Received May 14, 2020
Revised August 12, 2020
Accepted August 18, 2020
First published October 26, 2020.

Online issue publication

January 12, 2021

Supplementary Data

This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Data supplement 1
Data supplement 2
Data supplement 3
Supplementary Data

This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Data supplement 1
Data supplement 2
Data supplement 3
Supplementary Data

This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Data supplement 1
Data supplement 2
Data supplement 3

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Supplementary Data

Supplementary Data

Supplementary Data

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password